Movatterモバイル変換

[0]ホーム
URL:

MX2011011333A - Compositions and methods for treating insulin resistance and diabetes mellitus. - Google Patents

Compositions and methods for treating insulin resistance and diabetes mellitus.

Info

Publication number
MX2011011333A
MX2011011333AMX2011011333AMX2011011333AMX2011011333AMX 2011011333 AMX2011011333 AMX 2011011333AMX 2011011333 AMX2011011333 AMX 2011011333AMX 2011011333 AMX2011011333 AMX 2011011333AMX 2011011333 AMX2011011333 AMX 2011011333A
Authority
MX
Mexico
Prior art keywords
fluids
electrokinetically
altered
membrane
insulin resistance
Prior art date
Application number
MX2011011333A
Other languages
Spanish (es)
Inventor
Anthony B Wood
Gregory J Archambeau
Richard L Watson
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revalesio CorpfiledCriticalRevalesio Corp
Publication of MX2011011333ApublicationCriticalpatent/MX2011011333A/en

Links

Classifications

Landscapes

Abstract

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
MX2011011333A2009-04-272010-04-27Compositions and methods for treating insulin resistance and diabetes mellitus.MX2011011333A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US17313409P2009-04-272009-04-27
PCT/US2010/032620WO2010126908A1 (en)2009-04-272010-04-27Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (1)

Publication NumberPublication Date
MX2011011333Atrue MX2011011333A (en)2011-11-18

Family

ID=43032520

Family Applications (1)

Application NumberTitlePriority DateFiling Date
MX2011011333AMX2011011333A (en)2009-04-272010-04-27Compositions and methods for treating insulin resistance and diabetes mellitus.

Country Status (9)

CountryLink
EP (1)EP2424507A4 (en)
JP (2)JP2012525396A (en)
CN (1)CN102413817B (en)
AU (1)AU2010241736B2 (en)
BR (1)BRPI1013992A2 (en)
CA (1)CA2758738A1 (en)
IL (1)IL215925A0 (en)
MX (1)MX2011011333A (en)
WO (1)WO2010126908A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
PE20080251A1 (en)2006-05-042008-04-25Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
BRPI0711558A2 (en)2006-05-042011-11-08Boeringer Ingelheim Internat Gmbh polymorphs
EP1852108A1 (en)2006-05-042007-11-07Boehringer Ingelheim Pharma GmbH & Co.KGDPP IV inhibitor formulations
US9745567B2 (en)2008-04-282017-08-29Revalesio CorporationCompositions and methods for treating multiple sclerosis
US9523090B2 (en)2007-10-252016-12-20Revalesio CorporationCompositions and methods for treating inflammation
US10125359B2 (en)2007-10-252018-11-13Revalesio CorporationCompositions and methods for treating inflammation
PE20140960A1 (en)2008-04-032014-08-15Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
US20200155558A1 (en)2018-11-202020-05-21Boehringer Ingelheim International GmbhTreatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN104887389B (en)2009-01-292017-06-23弗赛特影像4股份有限公司Posterior segment drug delivery
US8623395B2 (en)2010-01-292014-01-07Forsight Vision4, Inc.Implantable therapeutic device
US10166142B2 (en)2010-01-292019-01-01Forsight Vision4, Inc.Small molecule delivery with implantable therapeutic device
PT2600812T (en)2010-08-052021-11-09Forsight Vision4 IncImplantable therapeutic device
US10617557B2 (en)2010-08-052020-04-14Forsight Vision4, Inc.Combined drug delivery methods and apparatus
LT2600930T (en)2010-08-052021-04-12Forsight Vision4, Inc.Injector apparatus for drug delivery
KR20130091759A (en)2010-08-122013-08-19레발레시오 코퍼레이션Compositions and methods for treatment of taupathy
KR102117282B1 (en)*2010-11-152020-06-01베링거 인겔하임 인터내셔날 게엠베하Vasoprotective and cardioprotective antidiabetic therapy
US9034883B2 (en)2010-11-152015-05-19Boehringer Ingelheim International GmbhVasoprotective and cardioprotective antidiabetic therapy
WO2012068549A2 (en)2010-11-192012-05-24Forsight Vision4, Inc.Therapeutic agent formulations for implanted devices
EA201391521A1 (en)*2011-04-132014-03-31Ревалезио Корпорейшн COMPOSITIONS AND METHODS FOR INHIBITING AND / OR MODULATING EFFECTOR T-CELLS PARTICIPATING IN THE INFLAMMATORY NEURODEGENERATIVE DISEASE
US10398592B2 (en)2011-06-282019-09-03Forsight Vision4, Inc.Diagnostic methods and apparatus
HRP20210676T1 (en)2011-09-162021-05-28Forsight Vision4, Inc.Fluid exchange apparatus
WO2013116061A1 (en)2012-02-032013-08-08Forsight Vision4, Inc.Insertion and removal methods and apparatus for therapeutic devices
ES2929025T3 (en)2012-05-142022-11-24Boehringer Ingelheim Int Linagliptin, a xanthine derivative as a dpp-4 inhibitor, for use in the treatment of SIRS and/or sepsis
JP6159584B2 (en)*2012-06-142017-07-05松本　高明 Infusion, infusion production method and infusion device
CH706747A2 (en)*2012-07-172014-01-31Hanspeter Steffen Process for hydration, tightening and care of the skin, for the treatment of dermatoses, sunburn and general wounds with electrolysis water produced with diamond electrodes.
GB201300684D0 (en)2013-01-152013-02-27Apitope Int NvPeptide
WO2014152959A1 (en)2013-03-142014-09-25Forsight Vision4, Inc.Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (en)2013-03-282024-06-11Forsight Vision4 Inc Ophthalmic implant for administration of therapeutic substances
US20170056438A1 (en)*2014-10-172017-03-02Aqua Zest CorporationNanobubble-containing composition and use thereof
HK1223975A1 (en)*2013-12-272017-08-11水活力株式会社Nanobubble-containing composition and use thereof
ES2803102T3 (en)2014-07-152021-01-22Forsight Vision4 Inc Eye implant delivery device
WO2016022750A1 (en)2014-08-082016-02-11Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016077371A1 (en)2014-11-102016-05-19Forsight Vision4, Inc.Expandable drug delivery devices and method of use
JP6674748B2 (en)*2015-05-272020-04-01花王株式会社 GLP-1 secretagogue
US11432959B2 (en)2015-11-202022-09-06Forsight Vision4, Inc.Porous structures for extended release drug delivery devices
MX2018012021A (en)2016-04-052019-01-24Forsight Vision4 IncImplantable ocular drug delivery devices.
CN105878194A (en)*2016-06-072016-08-24沈阳药科大学Glibenclamide nanocrystal preparation and preparation method thereof
KR102391564B1 (en)2016-06-102022-04-29베링거 인겔하임 인터내셔날 게엠베하 Combination of Linagliptin and Metformin
CN106362166B (en)*2016-10-272019-12-10武汉大学Function and application of tumor necrosis factor receptor-related pan-scaffold and signaling protein in treatment of fatty liver and type II diabetes
AU2018372806B2 (en)2017-11-212024-05-30Forsight Vision4, Inc.Fluid exchange apparatus for expandable port delivery system and methods of use
CN110006871A (en)*2019-02-202019-07-12常州大学 A cellular model based on exogenous histamine detection and its application
USD1033637S1 (en)2022-01-242024-07-02Forsight Vision4, Inc.Fluid exchange device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO1992005792A1 (en)*1990-10-021992-04-16Buchholz Klaus LUse of the reaction product of a gas and a liquid, as well as process and device for producing the same
US7196164B2 (en)*1997-07-082007-03-27Human Genome Sciences, Inc.Secreted protein HHTLF25
US6861227B2 (en)*1998-03-192005-03-01Human Genome Sciences, Inc.Antibodies to cytokine receptor common gamma chain like
JP2004529090A (en)*2001-02-012004-09-24ハイドロン テクノロジーズ，インク． Hyperoxygenated compositions and methods for supplying oxygen to tissue
US6902902B2 (en)*2001-11-272005-06-07Arena Pharmaceuticals, Inc.Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US20060273016A1 (en)*2005-06-032006-12-07BAGLEY DavidMethod for preparing water with a stable negative oxidation reduction potential (ORP)
US8591957B2 (en)*2006-10-252013-11-26Revalesio CorporationMethods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
AU2007308838B2 (en)*2006-10-252014-03-13Revalesio CorporationMixing device and output fluids of same
US20080154795A1 (en)*2006-12-252008-06-26Amos AlonAuction platform and applications
JP2008156320A (en)*2006-12-262008-07-10Hydrox Kk Antioxidant functional water
MX2010004563A (en)*2007-10-252010-07-28Revalesio CorpCompositions and methods for modulating cellular membrane-mediated intracellular signal transduction.
US20090227018A1 (en)*2007-10-252009-09-10Revalesio CorporationCompositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Also Published As

Publication numberPublication date
CA2758738A1 (en)2010-11-04
IL215925A0 (en)2011-12-29
CN102413817B (en)2014-12-17
BRPI1013992A2 (en)2016-08-16
EP2424507A1 (en)2012-03-07
JP2015229678A (en)2015-12-21
JP2012525396A (en)2012-10-22
AU2010241736A1 (en)2011-12-22
CN102413817A (en)2012-04-11
EP2424507A4 (en)2012-10-24
WO2010126908A1 (en)2010-11-04
AU2010241736B2 (en)2016-01-28

Similar Documents

PublicationPublication DateTitle
MX2011011333A (en)Compositions and methods for treating insulin resistance and diabetes mellitus.
MX337862B (en)Compositions and methods for treating multiple sclerosis.
WO2009134929A3 (en)Compositions and methods for treating digestive disorders
MX2010004554A (en)Compositions and methods for treating inflammation.
MX2013001636A (en)Compositions and methods for treatment of taupathy
VanceMAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond
EA201170601A1 (en) MODULATORS OF TRANSMEMBRANE CONDUCTIVITY REGULATOR IN MUKOVISCHIDOZA
BR112014010275A2 (en) diabetes treatment formulations
BR112012031329A2 (en) vstm3 dimeric fusion proteins and related compositions and methods
CR10852A (en) BICYCLE COMPOUNDS AND ITS USE AS ANTI-DIABETICS
ATE524482T1 (en) LOW VISCOSITY IONIC LIQUIDS
CU20120116A7 (en) POLIPEPTIDES THAT LINK TO DR5 HUMAN WITH AGONIST EFFECTS, THAT INCLUDE ONE OR MORE MONOMERS OF A SINGLE VARIABLE DOMAIN, USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH DR5
CL2009000048A1 (en) Use of compounds derived from triterpenoids in the treatment of kidney failure, and associated diseases such as: nephropathies, insulin resistance, diabetes, vascular pathologies, among others.
MX384232B (en) CHOLESTOSOMIC VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS.
ATE548677T1 (en) IONIC LIQUID
CL2012003604A1 (en) Heterocyclic compounds derived from substituted pyridine carboxamide; Preparation process; pharmaceutical composition; pharmaceutical combination; use in the treatment of cell proliferative disorders, parkinson's disease, cancer, among others.
UA116665C2 (en)Growth differentiation factor 15 (gdf-15) constructs
BR112014018575A2 (en) Growth Differentiation Factor 15 Polypeptides (gdf-15)
WO2008027420A3 (en)Implantable devices for producing insulin
BR112012001975A2 (en) transparent electrochromic system
BR112012018374A2 (en) pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in the treatment of metabolic disorders as g-protein coupled receptor agonists (gpr43).
UA117480C2 (en)Treatment of diabetes mellitus by long–acting formulations of insulins
GT201000119A (en) "PROCEDURE FOR THE PREPARATION OF A FERMENTED DRINK"
ITMI20080570A1 (en) PROCEDURE FOR THE PREPARATION OF POLYBUTADIENE BRANCHED HIGH CONTENT IN UNIT 1.4-CIS
ECSP066777A (en) FUROSEMIDE DERIVATIVES AS MODULATORS OF HM74 AND ITS USE FOR INFLAMMATION TREATMENT

Legal Events

DateCodeTitleDescription
FGGrant or registration
[8]ページ先頭
©2009-2025 Movatter.jp